- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
BillionToOne Launches Expanded Fetal Antigen NIPTs
New Tests Detect Red Blood Cell and Platelet Antigens, Setting New Standard in Prenatal Care
Published on Feb. 10, 2026
Got story updates? Submit your updates here. ›
BillionToOne, a molecular diagnostics company, announced the launch of its expanded UNITY Red Blood Cell (RBC) Fetal Antigen NIPT and a first-of-its-kind Platelet Fetal Antigen NIPT. These tests enable non-invasive determination of fetal antigen status for pregnancies affected by or at risk of Hemolytic Disease of the Fetus and Newborn (HDFN) and Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), conditions that affect 1.5-2.5% of pregnancies.
Why it matters
The expanded UNITY Fetal Antigen NIPTs provide more comprehensive and definitive answers earlier in pregnancy, enabling clinicians to focus attention and resources on fetuses truly at risk while sparing antigen-negative pregnancies from unnecessary surveillance. This approach redefines the standard of care for HDFN and FNAIT, two underserved conditions that can lead to severe complications for the fetus.
The details
The UNITY RBC Fetal Antigen NIPT now covers 10 additional red blood cell antigens, increasing coverage to approximately 99% of antigens associated with HDFN. The new Platelet Fetal Antigen NIPT is the first-and-only non-invasive test to determine platelet antigen incompatibility, enabling proactive risk stratification for pregnancies at risk of FNAIT. Both tests provide early, accurate determination of fetal antigen status, with studies demonstrating >99.9% sensitivity and specificity.
- BillionToOne announced the launch of the expanded tests on February 9, 2026.
The players
BillionToOne
A next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all.
Dr. Oguzhan Atay
Co-Founder and CEO of BillionToOne.
What they’re saying
“We have a proven track record of building tests that close gaps in care and improve clinical decision-making. By expanding fetal antigen coverage for HDFN to encompass nearly all clinically relevant antigens, we are delivering more comprehensive and definitive answers earlier in pregnancy. We are also applying the same approach to platelet antigen incompatibility in a first-of-its-kind offering.”
— Dr. Oguzhan Atay, Co-Founder and CEO of BillionToOne (Press Release)
What’s next
The expanded UNITY Fetal Antigen NIPTs are expected to contribute to recent clinical guideline changes, including the recent expert practice guideline update published in JAMA Network that recommends the use of cfDNA testing to determine fetal antigen status.
The takeaway
BillionToOne's expanded UNITY Fetal Antigen NIPTs set a new standard in the management of fetal antigen incompatibility, including both HDFN and FNAIT. By enabling early, non-invasive determination of both red blood cell and platelet fetal antigens, these tests provide clarity for pregnant patients who need it the most, sparing antigen-negative pregnancies from unnecessary surveillance while allowing clinicians to focus on fetuses truly at risk.
